1-1 of 1
ReFacto STL Study Group
Close
Save search
Sort by
Journal Articles

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Free
Jay M. Feingold, MD, PhD, Mark P. Smith, MD, Richard Littlewood, MD, Paul Giangrande, MD, ReFacto STL Study Group
Journal: Blood
Blood (2004) 104 (11): 4023.
https://doi.org/10.1182/blood.V104.11.4023.4023
Published: 2004